title: Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model.
abstract: Tyrosinase-related protein (TRP) 2 belongs to the melanocyte differentiation antigens and has been implicated as a target for immunotherapy of human as well as murine melanoma. In the current report, we explored the efficacy of nonmutated epitopes with differential binding affinity for MHC class I, derived from mouse TRP2 to induce CTL-mediated, tumor-reactive immunity in vivo within the established B16 melanoma model of C57BL/6 mice. The use of nonmutated TRP2-derived epitopes for vaccination provides a mouse model that closely mimics human melanoma without introduction of xenogeneic or otherwise foreign antigen. The results demonstrate that vaccination with TRP2 peptide-loaded bone marrow-derived dendritic cells (DCs) results in activation of high avidity TRP2-specific CTLs, displaying lytic activity against both B16 melanoma cells and normal melanocytes in vitro. In vivo, protective antitumor immunity against a lethal s.c. B16 challenge was observed upon DC-based vaccination in this fully autologous tumor model. The level of protective immunity positively correlated with the MHC class I binding capacity of the peptides used for vaccination. In contrast, within this autologous model, vaccination with TRP2 peptide in Freund's adjuvant or TRP2-encoding plasmid DNA did not result in protective immunity against B16. Strikingly, despite the observed CTL-mediated melanocyte destruction in vitro, melanocyte destruction in vivo was sporadic and primarily restricted to minor depigmentation of the vaccination site. These results emphasize the potency of DC-based vaccines to induce immunity against autologous tumor-associated antigen and indicate that CTL-mediated antitumor immunity can proceed without development of adverse autoimmunity against normal tissue.
authors.affiliation: Department of Tumor Immunology, University Medical Center St. Radboud, Philips van Leydenlaan, Nijmegen, The Netherlands.
authors.forename: M W
authors.initials: MW
authors.lastname: Schreurs
authors.forename: A A
authors.initials: AA
authors.lastname: Eggert
authors.forename: A J
authors.initials: AJ
authors.lastname: de Boer
authors.forename: J L
authors.initials: JL
authors.lastname: Vissers
authors.forename: T
authors.initials: T
authors.lastname: van Hall
authors.forename: R
authors.initials: R
authors.lastname: Offringa
authors.forename: C G
authors.initials: CG
authors.lastname: Figdor
authors.forename: G J
authors.initials: GJ
authors.lastname: Adema
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000941:Antigens / Q000276:immunology*; D002478:Cells, Cultured; D002851:Chromatography, High Pressure Liquid; D002857:Chromium / Q000378:metabolism; D003713:Dendritic Cells / Q000276:immunology*; D004305:Dose-Response Relationship, Drug; D000939:Epitopes; D005805:Genes, MHC Class I / Q000276:immunology; D006801:Humans; D020128:Inhibitory Concentration 50; D008285:Major Histocompatibility Complex / Q000276:immunology; D008297:Male; D008544:Melanocytes / Q000166:cytology*; D008545:Melanoma / Q000276:immunology*; D008546:Melanoma, Experimental / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D008969:Molecular Sequence Data; D009154:Mutation; D010455:Peptides / Q000378:metabolism; D010957:Plasmids / Q000378:metabolism; D013602:T-Lymphocytes, Cytotoxic / Q000378:metabolism; D013997:Time Factors; D014407:Tumor Cells, Cultured
chemical_list: D000941:Antigens; D000939:Epitopes; D010455:Peptides; D002857:Chromium